SemBioSys initiates toxicology study for safflower-produc... (that safflower-produced insulin isphysic...)

SemBioSys initiates toxicology study for safflower-produced insulin

Date:3/26/2008

that safflower-produced insulin is physically, structurally and physiologically indistinguishable from pharmaceutical-grade human recombinant insulin in laboratory testing. In a standard quantitative blood sugar assay performed in rabbits (insulin tolerance test), SemBioSys has demonstrated the pharmacodynamic equivalence of safflower-produced insulin to pharmaceutical-grade insulin. Thus the completion of this toxicology study fulfills the pre-requisite for filing the IND.

The world market for insulin is US$7.1 billion today and the demand for insulin is projected to increase due to two factors. Demographic and dietary choices in the western world are causing an increase in the incidence of diabetes. At the same time, countries in the rest of the world, that are currently underserved in the insulin market, are demanding greater access to insulin at an affordable price. By 2012, independent estimates predict a US$15 billion insulin market. SemBioSys' plant-made insulin will offer dramatic capital and operating cost reductions with the potential to enter the market as a low-cost source of insulin to meet this exploding demand.

About SemBioSys Genetics Inc. (http://www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and agricultural biotechnology markets.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan
'/>"/>

1

GOOD

Page: 1 2 3
Related biology technology :

1. SemBioSys announces 2007 financial and operational results
2. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
3. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
4. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
5. SemBioSys signs option agreement for safflower-produced food ingredient
6. SemBioSys announces 2007 third quarter results
7. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
8. SemBioSys updates Apo AI development program
9. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
10. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
11. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia

Post Your Comments:

SemBioSys initiates toxicology study for safflower-produc...(that safflower-produced insulin isphysic...)